Zobrazeno 1 - 10
of 88
pro vyhledávání: '"M Catherine Pietanza"'
Autor:
Laura C Cappelli, Maria E Suarez-Almazor, Michelle Turner, Stephane Champiat, Caroline Robert, Julie R Brahmer, Jarushka Naidoo, Jeffrey Weber, Joanne Riemer, Elad Sharon, Michael B Atkins, M Catherine Pietanza, Karthik Suresh, Catherine Murphy, Javid Moslehi, David Feltquate, Lee M Krug
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy may vary substantially in their clinical presentation, including natural history, outcomes to treatment, and patterns. The application of clinical guideli
Externí odkaz:
https://doaj.org/article/ce3651e8e8104a2ca8905bdbc8dd0dd4
Autor:
Enriqueta Felip, Marina Chiara Garassino, Edward B Garon, Roy S Herbst, Razvan Cristescu, Martin Reck, Yi-Long Wu, Byoung Chul Cho, Michael Boyer, Delvys Rodriguez-Abreu, Hidehito Horinouchi, Rina Hui, Gilberto de Castro, Gilberto Lopes, Dariusz M Kowalski, Hande Z Turna, Tony SK Mok, Shirish M Gadgeel, Kazuo Kasahara, Julie Kobie, Yongjin Li, Mark A Ayers, M Catherine Pietanza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d2df9b39abf04ab5b7dd2385fd5704bb
Autor:
Matthew Hellmann, Ying Cheng, Toshiaki Takahashi, Gilberto de Castro, M Catherine Pietanza, James Chih-Hsin Yang, Byoung Cho, Rosalyn Juergens, Mustafa Erman, Jessica Bauman, Paul Schwarzenberger, Pingye Zhang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/2116ff1baf5349cfbe8aac848a2def32
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectivesImmune checkpoint inhibitors (ICIs) of programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) have been rapidly adopted in US clinical practice for first-line therapy of metastatic non-small cell lung cancer (NSCLC) since regul
Externí odkaz:
https://doaj.org/article/472308c0037f48ea8ad274b4f94563d6
Autor:
Marina C. Garassino, Shirish Gadgeel, Giovanna Speranza, Enriqueta Felip, Emilio Esteban, Manuel Dómine, Maximilian J. Hochmair, Steven F. Powell, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Takayasu Kurata, Jhanelle E. Gray, Paul Schwarzenberger, Erin Jensen, M. Catherine Pietanza, Delvys Rodríguez-Abreu
Publikováno v:
Scientia
Pembrolizumab; Non-small-cell lung cancer Pembrolizumab; Cáncer de pulmón de células no pequeñas Pembrolizumab; Càncer de pulmó de cèl·lules no petites Clinical trials frequently include multiple end points that mature at different times. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374e74c86ca13e92597e504ff2706d68
https://doi.org/10.1200/jco.22.01989
https://doi.org/10.1200/jco.22.01989
Publikováno v:
Lung Cancer. 176:132-139
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7535ae4e3ec4f42ad976829577a1ff4b
https://doi.org/10.1016/j.lungcan.2023.01.003
https://doi.org/10.1016/j.lungcan.2023.01.003
Autor:
Yuting Kuang, Rajpal Singh, Arianna Nevo, Anne C. Deitz, M. Catherine Pietanza, Aixue Liu, Jennifer Uyei, Ke Zu
Publikováno v:
Clinical Lung Cancer. 23:659-669
Severe pneumonitis (≥ grade 3 by Common Terminology Criteria for Adverse Events [CTCAE]) is a toxicity associated with concurrent chemoradiation therapy (CCRT), which is the standard first-line treatment for patients with limited-stage small cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8f8f1ec69fd245493bf550a92ce349a
https://doi.org/10.1016/j.cllc.2022.09.008
https://doi.org/10.1016/j.cllc.2022.09.008
Autor:
Lee M. Krug, Mark G. Kris, Gregory J. Riely, Christopher G. Azzoli, Naiyer A. Rizvi, Timothy A. Chan, Andrei I. Holodny, Michelle S. Ginsberg, Adriana Heguy, William D. Travis, Dyana K. Sumner, John J. Fiore, Camelia S. Sima, Kety Huberman, Kyuichi Kadota, M. Catherine Pietanza
PDF file - 39K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a3040e360d2af948eb11e1725328e81
https://doi.org/10.1158/1078-0432.22443855
https://doi.org/10.1158/1078-0432.22443855
Autor:
Lee M. Krug, Mark G. Kris, Gregory J. Riely, Christopher G. Azzoli, Naiyer A. Rizvi, Timothy A. Chan, Andrei I. Holodny, Michelle S. Ginsberg, Adriana Heguy, William D. Travis, Dyana K. Sumner, John J. Fiore, Camelia S. Sima, Kety Huberman, Kyuichi Kadota, M. Catherine Pietanza
PDF file - 55K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5169fcc4ed19230bb7c0a5915a7e797e
https://doi.org/10.1158/1078-0432.22443852
https://doi.org/10.1158/1078-0432.22443852
Autor:
Marina C. Garassino, Shirish Gadgeel, Silvia Novello, Balazs Halmos, Enriqueta Felip, Giovanna Speranza, Rina Hui, Edward B. Garon, Hidehito Horinouchi, Shunichi Sugawara, Delvys Rodriguez-Abreu, Martin Reck, Razvan Cristescu, Deepti Aurora-Garg, Andrey Loboda, Jared Lunceford, Julie Kobie, Mark Ayers, Bilal Piperdi, M. Catherine Pietanza, Luis Paz-Ares
Publikováno v:
Scientia
Biomarker; Pembrolizumab; Tissue tumor mutational burden Biomarcador; Pembrolizumab; Càrrega mutacional del tumor tissular Biomarcador; Pembrolizumab; Carga mutacional del tumor tisular Introduction We evaluated tissue tumor mutational burden (tTMB)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8488a9b32fcb55808ebaaf3099381eb9
https://hdl.handle.net/2318/1895736
https://hdl.handle.net/2318/1895736